
usd aug pm et
summari compani develop manufactur market proprietari specialti health care
product eye care women health
price-to-earnings oper ep
custom tend brand loyal come
contact lens howev off-set increas
competit contact lens new technolog
laser surgeri
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun pm stock trade
estim fy oct revenu rise
billion expand
fy aid acquisit
paragon vision scienc paragard iud
growth coopervis driven increas
sale toric multifoc
increas adopt daili lens
estim may market share
daili lens lower
market share reusabl lens impli
signific room growth
view novemb acquisit
paragard iud posit
see near-term growth mid-singl
digit although high potenti
product given low market penetr
annual iud market possibl
expect gross margin expand
slightli fy fy
fy reflect benefici
product mix shift higher sale leverag
off-set foreign currenc headwind
invest improv distribut label
packag capabl
think share trade
next-twelve-month earn near fair
valu grown key franchis
strateg expans invest
high-tech lens foreign market
taken market share larg competitor
win new wearer trade
exist user daili lens market
share gain mostli retain
consum stay contact len brand
year averag accord
select made expect
user transit daili contact
conveni hand
near-term growth could limit
competit dynam invest futur
growth cannib legaci
risk recommend target price
slowdown demand daili contact lens
weaker-than-expect growth emerg
target price reflect
price-to-earnings multipl ep
estim multipl high
end five-year rang
improv growth outlook
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview compani develop manufactur market health care
product two busi unit coopervis coopersurg csi account
net sale fy oct csi repres balanc
coopervis develop manufactur market broad rang contact lens world-wide vision
care market contact len market two major product categori spheric lens includ
lens correct nearsighted farsighted uncompl complex visual defect
toric multifoc lens includ lens addit correct nearsighted
farsighted address complex visual defect astigmat presbyopia sale fy
product categori broke follow single-us sphere non-singl use sphere toric
len multi-foc len fy sale geograph market america emea
asia-pacif
coopersurg offer broad array product servic focus advanc health famili
portfolio product servic focus women health includ medic devic
fertil genom diagnost contracept csi offer product technolog servic
clinician patient world-wide csi collabor clinician identifi product new
technolog dispos product diagnost test sophist instrument equip
bring new product market csi also compet global vitro fertil ivf market
product portfolio ivf media assist reproduct technolog solut design enhanc
work fertil profession benefit famili
major develop novemb acquir paragard product line teva
pharmaceut billion paragard intrauterin devic iud hormone-fre long
last revers contracept option approv fda iud repres larg grow
segment contracept market acquisit compani mani
market profil estim global soft contact len market grew calendar year
billion estim market share year ago tie alcon
number two johnson johnson estim market share primari growth driver
market continu daili lens grew year-over-year account
total market within daili lens silicon hydrogel lens growth driver
sale year-over-year advanc len technolog silicon hydrogel materi
could drive adopt contact lens compet technolog laser vision surgeri could
becom cheaper preval
financi trend fiscal year end octob sale billion
year-over-year reflect five-year compound annual growth rate compound-annual-growth-rate adjust ep grew
year-over-year reflect five-year compound-annual-growth-rate januari
compani moder level debt base net debt capit ratio leverag net
debt ebitda ratio
senior vice-president financ tax
chief account
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc august technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
base index
five-year market price perform aug
insignific amount product input
china addit
chines govern seek lower health
care cost provid better health care
henc think medic suppli
manufactur particularli
technolog advanc product better
insul industri trade deal
two countri ever materi
would better idea health
care suppli sub-industri would impact
believ eas trade tension
year-to-d june health
suppli rose exceed
gain
period health suppli
declin vs decreas
 composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
neutral fundament outlook
health care suppli sub-industri next
month anticip sub-industri
see slowdown revenu growth
vs slight slowdown
global macroeconom growth expect
tone around econom growth
think demand health care
suppli relat lower urgenc medic need
elect procedur could increas
risk exampl sale dentistri
orthodontist suppli compris
signific portion health care suppli
could pressur dental
procedur may less essenti end
consum mean type
procedur could delay consum feel
sub-industri robust sale growth
emerg market recent year
expect continu key growth driver
sub-industri slowdown emerg
market could significantli dampen growth
health care suppli manufactur
long run demand health care suppli
like continu driven age
possibl threat state health
care system lawsuit texa rule
afford act
unconstitut current
appeal expect upheld upon
appeal although think decis
could take coupl year reach late
march depart justic
doj revers opinion indic
support elimin
impact trade war appear mild
far medic suppli compani
especi sinc base health care
suppli manufactur seem sourc
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain buy opinion share cooper
compani inc maintain target in-lin
peer ep estim multipl near
averag coo five-year rang april-q ep vs
higher estim rais oct ep
april-q sale increas million coopervis revenu
million coopersurg revenu million
expect pro-forma revenu growth strong diversifi
growth asia pacif region continu momentum daili silicon
hydrogel lens coopersurg segment revenu growth driven coo
late acquisit paragard see potenti make strateg
acquisit near futur opportun present expect
pay debt /kevin huang cfa
compani inc rais target
fy oct ep estim line peer reflect sale
growth margin expans expect increas fy fy ep
estim report jan-q
oper ep vs consensu forma sale
increas growth vision partial off-set declin
surgic impact declin genet test see pro forma
sale growth fy driven vision market share gain recoveri
analyst research note compani news
et cfra keep hold opinion share cooper compani inc
lift target price base multipl
ep estim multipl high
end rang apr-q ep vs
exceed consensu estim adjust fy oct ep
fy ep apr-q sale
increas organ million coopervis revenu
grew organ million coopersurg csi revenu
expand organ million oper margin declin
quarter prior-year period primarili due
neg impact currenc also due increas sale
market activ paragard devic see potenti
misight product specialti contact lens aim slow
progress myopia children increas invest misight
work fda /kevin huang cfa
et cfra reiter hold opinion share cooper compani
inc rais target price
ep estim multipl high end
five-year rang improv growth outlook
lift oct ep ep
jan-q ep vs higher estim
jan-q sale increas million coopervis revenu
grew million coopersurg csi revenu expand
million jan-q year-over-year pro-forma growth particularli
strong emea asia pacif respect daili lens
continu signific growth driver rest industri
sale daili lens account world-wide market
estim user daili lens make market
also increas share daili len market
et cfra maintain hold opinion share cooper compani
inc maintain target price
ep multipl higher end coo
five-year rang improv growth outlook oct-q
ep vs lower estim lower
oct ep initi ep oct-q
sale increas million coopervis revenu
million coopersurg csi revenu pro forma
million under-perform expect reason
higher-than-expect cost incur maintain custom servic
face coo distribut center upgrad activ rapid growth
adopt daili silicon hydrogel product cannib legaci product
estim current market share daili lens lower
market share reusabl lens space impli
signific opportun growth /kevin huang cfa
et cfra lower opinion share cooper compani
inc hold buy maintain target
ep estim multipl
higher end coo five-year rang
appropri given recent higher growth margin profil july-q ep
vs lower estim lower oct
ep ep july-q sale
increas million coopervis revenu
million coopersurg csi revenu coo lower ep
quarter due higher interest expens lower oper margin
invest sell market think thesi
mostli play limit near-term upsid invest
futur growth opportun result downward revis ep
estim henc lower opinion share hold /kevin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
